Drug Trial Radar · NCT06456463
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
85
Actual
Start
Jan 14, 2025
Primary completion
Feb 9, 2028
Study completion Feb 11, 2030
Sponsor
- Lead sponsor
- Stemline Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2 in 2 cohorts (TP53 mutated and TP53 wild type). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy.
Conditions
- Acute Myeloid Leukemia
Interventions
TagraxofuspDrug
Tagraxofusp will be administered by intravenous infusion for 3 consecutive days during each 28-day cycle.
VenetoclaxDrug
Venetoclax will be administered as an oral tablet (400 milligrams \[mg\]) daily, with ramp up in Cycle 1, and should be continued at target dose (400 mg) for the remainder of Cycle 1 and subsequent cycles of 28 days each.
AzacitidineDrug
Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Determination of Part 2 Selected Dose of Tagraxofusp When Administered in Combination with Venetoclax and AzacitidineTime frame: Cycles 1-4 (up to 112 days; 28 days/cycle)
- Part 2: Number of Participants Achieving a Best Overall Response (BOR) of Complete Remission (CR)Time frame: Cycles 1-4 (up to 112 days; 28 days/cycle)
Locations
32 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
Stanford Health Care
Stanford, California
University of Miami
Miami, Florida
AdventHealth Cancer Institute
Orlando, Florida
University of Chicago
Chicago, Illinois
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Henry Ford Health System Brigitte Harris Cancer Pavillion
Detroit, Michigan
Washington University - Siteman Cancer Center
St Louis, Missouri
John Theurer Cancer Center - Hackensack Meridian Health
Hackensack, New Jersey
Rutgers Cancer Institute
New Brunswick, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
North Shore University Hospital
Manhasset, New York
NYU Langone Health
New York, New York
Columbia University Irving Medical Center
New York, New York
Novant Health Presbyterian Medical Center
Charlotte, North Carolina
Novant Health Derrick L Davis Cancer Center
Winston-Salem, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Sydney Kimmel (Thomas Jefferson University)
Philadelphia, Pennsylvania
Sarah Cannon, the Cancer Institute of HCA Healthcare
Nashville, Tennessee
Tennessee Oncology
Nashville, Tennessee
Baylor Scott & White Health
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Townsville Hospital
Douglas, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Medical Centre
Clayton, Victoria, Australia
St. Vincents Hospital
Fitzroy, Victoria, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.